WordPress hakkında
WordPress.org
Belgeler
WordPress öğrenin
Destek
Geri bildirim
Giriş yap
Kayıt ol
Etkinlikler
Takvimi görüntüle
Ara
İçeriğe atla
Turkish
Turkish
English
Spanish
French
Chinese
Arabic
Japanese
Russian
Ukrainian
Urdu
Vietnamese
Portuguese
Marathi
Korean
Kazakh
Indonesian
Hindi
German
Dutch
Bengali
Login
Become a Member
Ara
Search
About MPS
Close About MPS
Open About MPS
MPS Types
MPS I
(Hurler, Hurler-Scheie, Scheie Syndrome)
MPS II
(Hunter Syndrome)
MPS III
(Sanfilippo Syndrome)
MPS IV
(Morquio Syndrome)
MPS VI
(Maroteaux-Lamy Syndrome)
MPS VII
(Sly Syndrome)
ML II and ML III
(I-Cell Disease and Pseudo-Hurler Polydystrophy)
Educational Resources
Booklets & Guides
Videos
Archive
Courage Pages
MPS Treatments
Clinical Trials
Emerging Treatments
ERT
Get Support
Close Get Support
Open Get Support
Get Support
Newly Diagnosed
Become a Member
Membership Renewal
Support Programs
What We Do
Close What We Do
Open What We Do
What We Do
About Us
Meet Our Team
Our History
Financial Reports
Contact Us
Fundraise
Get Involved
Close Get Involved
Open Get Involved
Get Involved
Bağış Yapın
Advocate
Volunteer
Shop
News & Events
Close News & Events
Open News & Events
News & Events
News
Events
Living With Courage Blog
Podcast
Research
Close Research
Open Research
Research
Research Grants
Bağış Yapın
About MPS
MPS Types
MPS Treatments
Booklets & Guides
Videos
Archive
Courage Pages
Get Support
Newly Diagnosed
Become a Member
Membership Renewal
Support Programs
What We Do
About Us
Meet Our Team
Our History
Financial Reports
Contact Us
Get Involved
Bağış Yapın
Advocate
Volunteer
Shop
News & Events
News
Events
Living With Courage Blog
Podcast
Research
Research Grants
Bağış Yapın
Fundraise
Ev
Ara
Search
Facebook
Instagram
Linkedin
Youtube
X-twitter
Login
Gerencia de MPS y del ML
Mayıs 5, 2023
Click here to download.
Back to Archive
More From the Archives
AAV2/8-mediated expression of modified sulphamidase, liver targeting for improved secretion and brain delivery in IIIA Huntaway dog.
Read More
Gene Therapy for MPS IVA
Read More
Therapeutic Targeting of Wnt/β-Catenin Signaling to Improve Bone Formation in MPS VII
Read More
Targeting mTORCI and autophagy pathways to rescue the skeletal phenotype in MPS mouse models
Read More
Validation of small molecule therapeutic leads for treatment of MPS I disease
Read More
English
English
Deutsch
Español
Français
Italiano
Polski
Svenska
Suomi
Português
Română
Slovenščina
Slovenčina
Nederlands
Dansk
Ελληνικά
Čeština
Magyar
Lietuvių
Latviešu
Eesti
Hrvatski
Gaeilge
Български
Norsk
Türkçe
Bahasa Indonesia
Português (Brasil)
日本語
한국어
简体中文
العربية
Русский
हिन्दी
Українська
Srpski
Accessibility Adjustments
Powered by
OneTap
Hide Toolbar
Back
How long do you want to hide the accessibility toolbar?
Hide Toolbar Duration
Only for this session
24 hours
A Week
Not Now
Hide Toolbar
Select your accessibility profile
Vision Impaired Mode
Enhances website's visuals
Seizure Safe Profile
Clear flashes & reduces color
ADHD Friendly Mode
Focused browsing, distraction-free
Blindness Mode
Reduces distractions, improves focus
Epilepsy Safe Mode
Dims colors and stops blinking
Content
Bigger Text
Cursor
Line Height
Letter Spacing
Readable Font
Dyslexic Font
Align Text
Text Magnifier
Highlight Links
Colors
Invert Colors
Brightness
Contrast
Grayscale
Saturation
Orientation
Reading Line
Keyboard Navigation
Highlight Titles
Reading Mask
Hide Images
Highlight Al
Browser needs to be updated
Your browser doesn’t support speech output. Please update your browser or use one with speech synthesis enabled (e.g. Chrome, Edge, Safari).
How to Update?
Read Page
Mute Sounds
Stop Animations
Reset Settings
Turkish
English
Spanish
French
Chinese
Arabic
Japanese
Russian
Ukrainian
Urdu
Vietnamese
Portuguese
Marathi
Korean
Kazakh
Indonesian
Hindi
German
Dutch
Bengali
